The JASPER trial is a phase 1/2 study launching from the University of Michigan, takes a fundamentally different approach to castration-resistant prostate cancer by targeting the molecular machinery driving cancer plasticity from the start: the JAK/STAT inflammatory signaling axis. Understanding why this strategy makes biological sense requires stepping into what we now know about how […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! Another week of fighting against our common enemy. And another wave of new weapons.! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE. […]
The ANDROMEDA phase 2 trial represents an advancement in managing recurrent oligometastatic prostate cancer by directly pitting alpha-emitting 225Ac-PSMA-617 against the established beta-emitting 177Lu-PSMA-617 (Pluvicto), both combined with stereotactic body radiotherapy (SBRT). This head-to-head comparison stems from the need to address limitations in current therapies for patients whose cancer returns in 1-5 detectable spots on […]
Imagine you have a long string of DNA code, a million letters long. A new AI tool called AlphaGenome reads that code and predicts exactly what it does. It tells you how active genes are, how DNA folds open or closed, where proteins stick to it, and even how far-apart parts of DNA touch each […]
A promising study published this month in Science Advances introduces a promising “neuroimmunotherapy” nanocarrier called LipoNCs@pGSDMB, designed precisely for bone metastases like those in prostate cancer. This tiny, smart drug delivery system activates only in the high-oxidative-stress environment of bone tumors, fusing directly with cancer cell membranes to release its payload straight into the cell’s […]
SHR-A1921, also known as tizetatug rezetecan, represents a significant advancement in targeted cancer therapeutics, specifically designed to exploit TROP2 overexpression in aggressive malignancies including prostate cancer. This novel antibody-drug conjugate (ADC) has demonstrated compelling preclinical activity in prostate cancer models and encouraging early clinical results across multiple solid tumors, positioning it as a potential therapeutic […]
DCC-2812 is a new oral drug designed to fight advanced cancers, especially in the urinary and reproductive systems like kidney, bladder, and prostate cancers. It works by turning on a special stress response inside cancer cells that pushes them past their breaking point, leading to cell death. Cancer cells live in harsh environments with low […]
Preliminary results from an ongoing phase 1/2 trial combining docetaxel with the tumor-targeting IL-12 immunocytokine PDS01ADC (aka M9241) indicate promising early activity in patients with metastatic castration-resistant prostate cancer (mCRPC). The single-arm study, presented at the American Association for Cancer Research special conference on prostate cancer research, enrolled 16 patients with progressive mCRPC, most of […]
BNT324 (DB-1311) is rapidly emerging as one of the most promising new agents in metastatic castration-resistant prostate cancer (mCRPC), with a data package that is unusually strong for a first-in-class B7-H3–targeting antibody–drug conjugate and now compelling enough to justify a head‑to‑head Phase 3 trial against docetaxel. The reason it has attracted so much attention is […]
SKL35501 is an emerging radiopharmaceutical therapy that embodies much of what “next‑generation oncology” is supposed to mean: precise targeting, potent cell kill, and a built‑in companion diagnostic strategy. In January 2026, the US FDA cleared SKL35501 and its imaging partner SKL35502 for a phase 1 Investigational New Drug (IND). SKL35501 originated as FL‑091, a small‑molecule […]